

## Rusan Pharma unveils indigenously developed APOSAN® 3ml Pen for management of Parkinson's Disease

31 March 2026 | News

**Company now offers the complete range of Apomorphine Hydrochloride in different fill volumes**



Rusan Healthcare, the marketing and distribution arm of Mumbai-based Rusan Pharma, has announced the launch of the multi-dose delivery pen device - APOSAN® 3ml Pen (Apomorphine Hydrochloride solution for injection in cartridge)(10 mg/ml)(3 ml pre-filled cartridges) for treatment of motor fluctuations commonly known as 'ON-OFF' episodes in patients suffering from Parkinson's disease (PD).

In 2018, Rusan was the first company in India to launch APOSAN® Apomorphine Hydrochloride solution for injection (10 mg/ml) (2ml and 5ml ampoules). Since APOSAN®'s launch in India, Rusan has observed remarkable clinical impact and consistently positive patient experiences, underscoring Apomorphine's value as a transformative option in Parkinson's management.

The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes, namely - 2ml injection, 3ml in pre-filled cartridge with a 'Multi-dose PEN device', and 5ml for continuous 'Infusion PUMPS' to meet distinct clinical scenarios in PD management, such as rapid rescue from OFF episodes using PEN devices and sustained symptom control using infusion PUMPS.

PD is estimated to affect nearly 10 to 11.7 million people globally, with India accounting for a significant and growing share of

the patient population. However, the clinical perception is shifting: Early-Onset Parkinson's Disease (EOPD), defined as diagnosis after the age of 20 years and before 50 years, now represents a growing share of the global burden, with incidence and prevalence tripling between 1990 and 2021.

The APOSAN® 3ml PEN offers a multi-dose, dial-a-dose mechanism with an enhanced dose-visibility window, thereby enabling accurate and consistent dose administration. The APOSAN® 3ml PEN reduces handling complexity and supports safer, more reliable self-administration, reducing the risk of dosing errors. The APOSAN® 3ml PEN device's lightweight, portable design enables convenient, dependable subcutaneous administration at home, empowering patients to manage their therapy promptly.